Adial Pharmaceuticals, Inc.

ADIL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $5.9M $3.8M $2.8M $4.0M $6.1M $4.4M $6.8M $3.9M
Accounts Receivable
Inventory
Total Current Assets $6.2M $4.1M $3.2M $4.8M $6.5M $5.1M $7.7M $4.7M
Property, Plant & Equipment $50.4K $58.1K
Goodwill $249.0K $249.0K
Intangible Assets (Excl. Goodwill) $2.8K $3.3K $3.9K $4.5K $5.0K $5.6K $6.2K $6.7K
Total Assets $6.7M $5.0M $4.7M $5.7M $7.5M $5.5M $7.7M $4.7M
Liabilities
Accounts Payable $655.2K $250.1K $103.3K $276.4K $286.2K $648.7K $190.2K $99.7K
Total Current Liabilities $1.4M $975.9K $653.1K $1.8M $2.7M $1.5M $539.1K $258.0K
Long-Term Debt
Total Liabilities $1.4M $975.9K $653.1K $2.5M $4.0M $1.5M $539.1K $258.0K
Stockholders' Equity
Retained Earnings $-90.0M $-82.0M $-68.8M $-63.7M $-50.9M $-31.5M $-20.6M $-12.0M
Total Stockholders' Equity $5.3M $4.1M $4.1M $3.3M $3.5M $4.0M $7.1M $4.4M
← Newer Page 1 of 2 Older →